SK Capital acquires Swixx BioPharma: the advisors
US-based private equity investor SK Capital has aquired Swixx BioPharma Group, a globally active partner in the distribution of biopharmaceutical products with a particular focus to Central and Eastern Europe and Latin America.
In connection with the deal Bär & Karrer advised the buyer, while Homburger represented Biocorp, which, together with the founders and other shareholders, will reinvest in Swixx BioPharma alongside SK Capital.
The Bär & Karrer team
Christoph Neeracher (pictured above – left) and Philippe Seiler (pictured above – right) led the Bär & Karrer also includes Therry Lehmann, Thomas Rohde, Romina Lauper, Rahel Brüschweiler, Markus Mezger, Max Winnenburg (all M&A), Susanne Schreiber, Martin Leu, and Leotrim Berisha (tax), Markus Wang and Christine Schweikard (IP/IT), Mani Reinert, Li Wei Dutler, and Martin Werner (competition), Christian Kunz and Katharina Cardon (data protection), Markus Schott, Julia Stempfel, and Jan Grossniklaus (regulatory), Rocco Rigozzi and Patrick Neher (real estate), Laura Widmer and Manuel Schmid (employment), Ralph Malacrida and Colin Giezendanner (financing), and Mariel Hoch (public M&A).
The Homburger team
The Homburger team working on the matter includes Andreas Müller (pictured), Claude Lambert, and Hans Glent Abildgaard — all corporate and M&A.
